TAK vs HLN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TAK Captures Institutional Edge (2โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Valuation, Momentum & Technical while HLN counters with relative strength in Growth & Margin. Fundamentally, TAK trades at 12.7x Forward P/E with 16.6% operating margin (+6.7% YoY revenue) versus HLN at 15.2x Forward P/E and 23.5% operating margin (+2.2% YoY). In options structure, TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro) against HLN sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TAK | HLN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $67.5B | $40.3B | Larger Scale | TAK |
| Trailing P/E Ratio Valuation | N/M | 18.8x | Lower Multiple | HLN |
| Forward P/E Ratio Valuation | 12.7x | 15.2x | Lower Multiple | TAK |
| Revenue Growth (YoY) Growth | +6.7% | +2.2% | Higher Growth | TAK |
| Operating Margin (TTM) Profitability | 16.6% | 23.5% | Higher Margin | HLN |
| Net Profit Margin Profitability | 0.9% | 14.5% | Higher Margin | HLN |
| Return on Equity (ROE) Capital Efficiency | 0.6% | 10.1% | Higher ROE | HLN |
| 52-Week Range Position Momentum | 97% ($14โ$22) | 28% ($8โ$11) | Stronger Trend | TAK |
| Beta / 30D Volatility Risk Regime | -0.02ฮฒ ยท 22% Vol | -0.02ฮฒ ยท 56% Vol | Lower Realized Risk | TAK |
| Unified Institutional Score Composite Signal | 47.7 / 100 (HOLD) | 44.6 / 100 (HOLD) | Higher Composite | TAK |